Dr. Unnikrishnan Nair R [N10193] – Trivandrum
The introduction of Anti Vascular Endothelial Growth Factors (Anti VEGF) drugs have revolutionized the limits to which the treatment of vascular chorio-retinal pathology can be taken. However from the exultation of the early days, now a sober realization and understanding of the limitations and applications of anti VEGF agents
is evolving. Numerous new concepts , drugs and adjuncts have been incorporated into the management creating new scenarios previously not considered. Adding to this, there are practical difficulties of repetitive usage, concerns about safety and data from trials that affect treatment decisions and outcomes. This course looks at the important facts on how to safely use Bevacizumab in your practice, real life issues about the usage of Anti VEGF in DME, the role and effect of the newer agent Aflibercept and effective ways to use PDT and Sustained release Dexamethasone to optimise treatment results.
| 1 | How to create a legally and ethically safe environment for using | Dr. Mahesh G |
| 2 | How to manage patient expectations and outcomes during repetitive use of Anti VEGF for DME (12 mins) | Dr. Gopal S Pillai |
| 3 | Does Aflibercept offer substantial advantages over the current stock of Anti VEGFs (12 mins) | Dr. Preetam Samant |
| 4 | Selective incorporation of sustained release steroids in this Anti VEGF dominated world (12 mins) | Dr. Unnikrishnan Nair R |
| 5 | Does PDT really increase the effectiveness of treatment in AMD? (12 mins) | Dr. Rupak Kanti Biswas |
| Panel Discussion : (15 mins.) |